Point72 Europe London LLP Invests $4.31 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Point72 Europe London LLP acquired 15,958 shares of Alnylam Pharmaceuticals, valued at approximately $4.3 million, during the first quarter.
• CEO Yvonne Greenstreet sold 19,297 shares for around $5.9 million, decreasing her position by 28.28%.
• Alnylam Pharmaceuticals reported a 17.3% year-over-year revenue growth and surpassed earnings estimates with an EPS of $0.32, compared to a consensus estimate of ($0.54).

Point72 Europe London LLP purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 15,958 shares of the biopharmaceutical company's stock, valued at approximately $4,309,000.

Other institutional investors have also bought and sold shares of the company. Panagora Asset Management Inc. grew its holdings in Alnylam Pharmaceuticals by 74.5% during the 1st quarter. Panagora Asset Management Inc. now owns 96,804 shares of the biopharmaceutical company's stock worth $26,139,000 after acquiring an additional 41,340 shares during the period. Orbis Allan Gray Ltd grew its holdings in Alnylam Pharmaceuticals by 11.0% during the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company's stock worth $441,462,000 after acquiring an additional 162,121 shares during the period. Vident Advisory LLC grew its holdings in Alnylam Pharmaceuticals by 101.0% during the 1st quarter. Vident Advisory LLC now owns 2,667 shares of the biopharmaceutical company's stock worth $720,000 after acquiring an additional 1,340 shares during the period. Kodai Capital Management LP acquired a new stake in Alnylam Pharmaceuticals during the 1st quarter worth about $5,713,000. Finally, Driehaus Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 70.6% during the 1st quarter. Driehaus Capital Management LLC now owns 57,128 shares of the biopharmaceutical company's stock worth $15,426,000 after acquiring an additional 23,648 shares during the period. Institutional investors own 92.97% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ALNY shares. Jefferies Financial Group increased their price target on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 9th. HC Wainwright reissued a "buy" rating and set a $570.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday. Oppenheimer raised shares of Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 price objective on the stock in a research report on Monday, August 4th. Finally, Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $412.79.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded up $6.11 during trading hours on Thursday, hitting $453.54. 714,263 shares of the company were exchanged, compared to its average volume of 959,894. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $469.81. The stock has a market capitalization of $59.45 billion, a price-to-earnings ratio of -183.62 and a beta of 0.32. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The firm has a fifty day simple moving average of $382.18 and a 200 day simple moving average of $306.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. During the same period in the previous year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals's revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the transaction, the executive vice president directly owned 20,221 shares in the company, valued at approximately $9,269,508.61. The trade was a 6.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis A. Ausiello sold 31,448 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares of the company's stock, valued at $397,724.38. This represents a 97.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 57,594 shares of company stock worth $25,551,456 in the last three months. Insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.